Diabetes and cancer risk: A Mendelian randomization study

Area of Science:

• Epidemiology
• Genetics
• Oncology

Background:

• Previous studies suggest a link between type 2 diabetes and increased cancer risk.
• However, residual confounding and reverse causality may affect these findings.
• The direct causal role of type 2 diabetes in cancer development remains unclear.

Purpose of the Study:

• To investigate the causal association between type 2 diabetes and cancer risk using Mendelian randomization.
• To clarify whether type 2 diabetes per se contributes to the development of overall and site-specific cancers.

Main Methods:

• A case-cohort study design was employed with 32,949 participants (10,536 subcohort, 3,541 cancer cases).
• Mendelian randomization analysis utilized 29 type 2 diabetes susceptibility variants and an inverse variance-weighted method.
• Hazard ratios were estimated for associations between genetically predicted type 2 diabetes and cancer risks.

Main Results:

• No significant association was found between genetically predicted type 2 diabetes and overall cancer risk (HR: 1.03, 95% CI: 0.92-1.15).
• No strong evidence supported associations with site-specific cancers, including pancreas, liver, and colorectum.
• Further analysis on colorectal cancer using large-scale GWAS data yielded a null association (HR: 1.00, 95% CI: 0.93-1.07).

Conclusions:

• This Mendelian randomization study provides no strong evidence for a causal role of type 2 diabetes in cancer development in the Japanese population.
• Findings suggest that the observed associations in previous studies may be due to confounding factors rather than a direct effect of diabetes.
• The genetic predisposition to type 2 diabetes does not appear to significantly increase cancer risk in this population.